NCT05039710View on ClinicalTrials.gov

A Study of JNJ-75220795 in Japanese Participants

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 8, 2021

Primary Completion Date

February 17, 2023

Study Completion Date

February 17, 2023

Conditions
Fatty Liver
Interventions
DRUG

JNJ-75220795

JNJ-75220795 will be administered as SC injection.

OTHER

Placebo

Matching placebo will be administered as SC injection.

Trial Locations (4)

813-0017

Souseikai Fukuoka Mirai Hospital, Fukuoka

160-0008

Medical Corporation Heishinkai ToCROM Clinic, Shinjuku-ku

565-0853

Heishinkai TOCROM Clinic, Suita

130-0004

Sumida Hospital, Tokyo

Sponsors
All Listed Sponsors
lead

Janssen Pharmaceutical K.K.

INDUSTRY

NCT05039710 - A Study of JNJ-75220795 in Japanese Participants | Biotech Hunter | Biotech Hunter